The NFE2L2 expression in pancreatic carcinoma, colorectal carcinoma, and glioblastoma cell lines was between 29%–73.7% with respect to the observed in Hs766T (Figure 10B). The gene discussed is NFE2L2; the disease is exocrine pancreatic carcinoma.